AGL 24.24 Increased By ▲ 0.77 (3.28%)
AIRLINK 107.70 Increased By ▲ 1.59 (1.5%)
BOP 5.12 Decreased By ▼ -0.05 (-0.97%)
CNERGY 3.63 Decreased By ▼ -0.03 (-0.82%)
DCL 7.32 Decreased By ▼ -0.48 (-6.15%)
DFML 42.10 Decreased By ▼ -2.09 (-4.73%)
DGKC 88.80 Increased By ▲ 0.30 (0.34%)
FCCL 21.75 No Change ▼ 0.00 (0%)
FFBL 41.85 Decreased By ▼ -0.67 (-1.58%)
FFL 8.61 Decreased By ▼ -0.14 (-1.6%)
HUBC 148.75 Increased By ▲ 0.95 (0.64%)
HUMNL 10.14 Decreased By ▼ -0.11 (-1.07%)
KEL 4.28 Decreased By ▼ -0.06 (-1.38%)
KOSM 3.59 Decreased By ▼ -0.20 (-5.28%)
MLCF 36.20 Decreased By ▼ -0.20 (-0.55%)
NBP 47.75 Decreased By ▼ -1.55 (-3.14%)
OGDC 129.10 Decreased By ▼ -1.75 (-1.34%)
PAEL 25.75 Decreased By ▼ -0.20 (-0.77%)
PIBTL 6.00 Decreased By ▼ -0.05 (-0.83%)
PPL 113.65 Decreased By ▼ -0.90 (-0.79%)
PRL 22.30 Decreased By ▼ -0.30 (-1.33%)
PTC 12.10 Decreased By ▼ -0.27 (-2.18%)
SEARL 54.98 Decreased By ▼ -0.72 (-1.29%)
TELE 7.11 Decreased By ▼ -0.14 (-1.93%)
TOMCL 37.11 Increased By ▲ 0.71 (1.95%)
TPLP 7.76 Decreased By ▼ -0.19 (-2.39%)
TREET 15.00 Decreased By ▼ -0.29 (-1.9%)
TRG 55.54 Decreased By ▼ -1.16 (-2.05%)
UNITY 31.20 Decreased By ▼ -0.65 (-2.04%)
WTL 1.15 Decreased By ▼ -0.02 (-1.71%)
BR100 8,248 Decreased By -46.7 (-0.56%)
BR30 25,878 Decreased By -223.8 (-0.86%)
KSE100 78,030 Decreased By -439.8 (-0.56%)
KSE30 25,084 Decreased By -114.2 (-0.45%)
Business & Finance

Moderna plans trial of altered COVID-19 vaccine booster to address South Africa variant

  • The company said the vaccine did not see any impact from the U.K. variant - which has been shown to be more transmissible - in the tests.
  • The company said it plans to publish data from its tests against the South African and U.K. variants on the website.
Published January 25, 2021

Moderna plans trial of altered COVID-19 vaccine booster to address South Africa variant

Moderna said on Monday it plans to start clinical trials of an altered booster version of its COVID-19 vaccine aimed at the South African variant after tests showed its authorised vaccine may produce a diminished antibody response.

It will also test an additional booster shot of its authorised vaccine in trials to see if it boosts antibody reaction against the South Africa variant. The current regimen is for two shots four weeks apart.

The company said in a press release that it was being cautious and that the two-dose regimen of the vaccine was still expected to be protective against the South African and other variants detected to date.

The company said the vaccine did not see any impact from the U.K. variant - which has been shown to be more transmissible - in the tests.

The company said it plans to publish data from its tests against the South African and U.K. variants on the website bioRxiv.

Comments

Comments are closed.